Vijay Kumar
Stock Analyst at Evercore ISI Group
(2.44)
# 2,405
Out of 5,163 analysts
289
Total ratings
45.2%
Success rate
-0.71%
Average return
Main Sectors:
Stocks Rated by Vijay Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAI Caris Life Sciences | Maintains: Outperform | $38 → $34 | $18.15 | +87.33% | 3 | Feb 27, 2026 | |
| PEN Penumbra | Maintains: Outperform | $340 → $360 | $336.18 | +7.09% | 3 | Feb 26, 2026 | |
| USB U.S. Bancorp | Maintains: In-Line | $60 → $65 | $51.00 | +27.45% | 8 | Feb 5, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Outperform | $95 → $98 | $70.77 | +38.48% | 6 | Feb 5, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $112 → $96 | $69.13 | +38.87% | 8 | Feb 5, 2026 | |
| AZTA Azenta | Maintains: Outperform | $50 → $45 | $21.42 | +110.08% | 10 | Feb 5, 2026 | |
| TWST Twist Bioscience | Maintains: Outperform | $42 → $52 | $43.28 | +20.15% | 7 | Feb 3, 2026 | |
| RVTY Revvity | Maintains: Outperform | $112 → $118 | $85.57 | +37.90% | 4 | Feb 3, 2026 | |
| ISRG Intuitive Surgical | Maintains: In-Line | $580 → $550 | $472.16 | +16.49% | 15 | Jan 23, 2026 | |
| ABT Abbott Laboratories | Maintains: Outperform | $144 → $138 | $108.03 | +27.74% | 18 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $168 → $223 | $200.25 | +11.36% | 9 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $79 → $78 | $75.12 | +3.83% | 17 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $105 | $103.57 | +1.38% | 8 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $18 | $16.20 | +11.11% | 12 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $14 → $12 | $7.93 | +51.32% | 13 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $94 → $120 | $93.20 | +28.76% | 15 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $194 → $210 | $113.00 | +85.84% | 3 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $155 → $160 | $111.51 | +43.48% | 8 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $410 → $405 | $336.77 | +20.26% | 13 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $142 | $118.94 | +19.39% | 9 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $88 → $92 | $81.81 | +12.46% | 15 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $525 → $590 | $464.37 | +27.05% | 13 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,275 → $1,400 | $1,173.74 | +19.28% | 12 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $226 → $245 | $187.32 | +30.79% | 4 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $31 | $17.40 | +78.16% | 8 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $103 → $106 | $87.14 | +21.64% | 5 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $46 | $22.99 | +100.09% | 4 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $3 | $2.97 | +1.01% | 6 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $18 → $30 | $12.06 | +148.76% | 11 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $335 → $355 | $286.57 | +23.88% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $160 | $77.96 | +105.23% | 7 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $286 → $290 | $159.36 | +81.98% | 6 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.14 | +514.04% | 1 | May 31, 2022 |
Caris Life Sciences
Feb 27, 2026
Maintains: Outperform
Price Target: $38 → $34
Current: $18.15
Upside: +87.33%
Penumbra
Feb 26, 2026
Maintains: Outperform
Price Target: $340 → $360
Current: $336.18
Upside: +7.09%
U.S. Bancorp
Feb 5, 2026
Maintains: In-Line
Price Target: $60 → $65
Current: $51.00
Upside: +27.45%
GE HealthCare Technologies
Feb 5, 2026
Maintains: Outperform
Price Target: $95 → $98
Current: $70.77
Upside: +38.48%
Boston Scientific
Feb 5, 2026
Maintains: Outperform
Price Target: $112 → $96
Current: $69.13
Upside: +38.87%
Azenta
Feb 5, 2026
Maintains: Outperform
Price Target: $50 → $45
Current: $21.42
Upside: +110.08%
Twist Bioscience
Feb 3, 2026
Maintains: Outperform
Price Target: $42 → $52
Current: $43.28
Upside: +20.15%
Revvity
Feb 3, 2026
Maintains: Outperform
Price Target: $112 → $118
Current: $85.57
Upside: +37.90%
Intuitive Surgical
Jan 23, 2026
Maintains: In-Line
Price Target: $580 → $550
Current: $472.16
Upside: +16.49%
Abbott Laboratories
Jan 23, 2026
Maintains: Outperform
Price Target: $144 → $138
Current: $108.03
Upside: +27.74%
Jan 13, 2026
Maintains: Outperform
Price Target: $168 → $223
Current: $200.25
Upside: +11.36%
Jan 5, 2026
Downgrades: In-Line
Price Target: $79 → $78
Current: $75.12
Upside: +3.83%
Jan 5, 2026
Downgrades: In-Line
Price Target: $105
Current: $103.57
Upside: +1.38%
Jan 5, 2026
Downgrades: In-Line
Price Target: $18
Current: $16.20
Upside: +11.11%
Jan 5, 2026
Downgrades: In-Line
Price Target: $14 → $12
Current: $7.93
Upside: +51.32%
Jan 5, 2026
Upgrades: Outperform
Price Target: $94 → $120
Current: $93.20
Upside: +28.76%
Jan 5, 2026
Upgrades: Outperform
Price Target: $194 → $210
Current: $113.00
Upside: +85.84%
Jan 5, 2026
Upgrades: Outperform
Price Target: $155 → $160
Current: $111.51
Upside: +43.48%
Oct 31, 2025
Maintains: Outperform
Price Target: $410 → $405
Current: $336.77
Upside: +20.26%
Oct 31, 2025
Maintains: Outperform
Price Target: $132 → $142
Current: $118.94
Upside: +19.39%
Oct 31, 2025
Maintains: Outperform
Price Target: $88 → $92
Current: $81.81
Upside: +12.46%
Oct 7, 2025
Maintains: Outperform
Price Target: $525 → $590
Current: $464.37
Upside: +27.05%
Oct 7, 2025
Maintains: Outperform
Price Target: $1,275 → $1,400
Current: $1,173.74
Upside: +19.28%
Oct 7, 2025
Maintains: Outperform
Price Target: $226 → $245
Current: $187.32
Upside: +30.79%
Oct 7, 2025
Maintains: Outperform
Price Target: $33 → $31
Current: $17.40
Upside: +78.16%
Jul 8, 2025
Maintains: Outperform
Price Target: $103 → $106
Current: $87.14
Upside: +21.64%
Jul 8, 2025
Maintains: Outperform
Price Target: $48 → $46
Current: $22.99
Upside: +100.09%
May 19, 2025
Maintains: In-Line
Price Target: $3
Current: $2.97
Upside: +1.01%
Dec 2, 2024
Upgrades: Outperform
Price Target: $18 → $30
Current: $12.06
Upside: +148.76%
Oct 1, 2024
Maintains: In-Line
Price Target: $335 → $355
Current: $286.57
Upside: +23.88%
Oct 1, 2024
Maintains: Outperform
Price Target: $120 → $160
Current: $77.96
Upside: +105.23%
Oct 1, 2024
Maintains: Outperform
Price Target: $286 → $290
Current: $159.36
Upside: +81.98%
May 31, 2022
Initiates: Outperform
Price Target: $7
Current: $1.14
Upside: +514.04%